ATE404192T1 - Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration - Google Patents

Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration

Info

Publication number
ATE404192T1
ATE404192T1 AT01958395T AT01958395T ATE404192T1 AT E404192 T1 ATE404192 T1 AT E404192T1 AT 01958395 T AT01958395 T AT 01958395T AT 01958395 T AT01958395 T AT 01958395T AT E404192 T1 ATE404192 T1 AT E404192T1
Authority
AT
Austria
Prior art keywords
nefiracetam
neurodegeneration
postischemic
treat
stroke
Prior art date
Application number
AT01958395T
Other languages
German (de)
English (en)
Inventor
Eiichi Otomo
Yoshiyuki Takasu
Original Assignee
Hamilton Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hamilton Pharmaceuticals Inc filed Critical Hamilton Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE404192T1 publication Critical patent/ATE404192T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AT01958395T 2001-08-22 2001-08-22 Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration ATE404192T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2001/007180 WO2003018005A1 (en) 2001-08-22 2001-08-22 use of nefiracetam for treating neurodegeneration

Publications (1)

Publication Number Publication Date
ATE404192T1 true ATE404192T1 (de) 2008-08-15

Family

ID=11737657

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01958395T ATE404192T1 (de) 2001-08-22 2001-08-22 Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration

Country Status (8)

Country Link
US (2) US20040192759A1 (enExample)
EP (1) EP1420782B1 (enExample)
JP (1) JP2005501108A (enExample)
AT (1) ATE404192T1 (enExample)
CA (1) CA2457982C (enExample)
DE (1) DE60135390D1 (enExample)
ES (1) ES2311537T3 (enExample)
WO (1) WO2003018005A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
RU2329804C2 (ru) * 2006-03-28 2008-07-27 Валентина Ивановна Ахапкина Вещество, обладающее нейротропной - нейромодуляторной активностью
BRPI0920342A2 (pt) * 2008-10-16 2020-06-23 The Johns Hopkins University Uso de um inibidor da proteína vesicular sináptica 2a (sv2a) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica para melhora da função cognitiva, uso de levitiracetam ou um sal farmaceuticamente aceitável do mesmo, uso de brivaracetam ou um sal farmaceuticamente aceitável do mesmo, uso do seletracetam ou um sal farmaceuticamente aceitável do mesmo
US8962676B2 (en) 2009-10-22 2015-02-24 University College Dublin, National University Of Ireland, Dublin Causal therapy of diseases or conditions associated with CNS or PNS demyelination
EP2533645B1 (en) * 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
CN107810002B (zh) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749700A (en) * 1984-10-23 1988-06-07 Nastech Pharmaceutical Co, Inc. Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
SK279285B6 (sk) * 1991-05-02 1998-09-09 Daiichi Pharmaceutical Co. Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
JP3388778B2 (ja) * 1991-05-02 2003-03-24 第一製薬株式会社 脳血管性痴呆改善剤
AU8131198A (en) * 1997-07-15 1999-02-10 Daiichi Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for amnesia
JPH1180027A (ja) * 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 向知性薬
US6423739B1 (en) * 2000-02-23 2002-07-23 Daiichi Pharmaceutical Co., Ltd. Method for aiding cerebral recovery following neurodegeneration

Also Published As

Publication number Publication date
US20080076820A1 (en) 2008-03-27
CA2457982C (en) 2009-11-03
US20040192759A1 (en) 2004-09-30
JP2005501108A (ja) 2005-01-13
EP1420782A1 (en) 2004-05-26
CA2457982A1 (en) 2003-03-06
EP1420782B1 (en) 2008-08-13
ES2311537T3 (es) 2009-02-16
DE60135390D1 (de) 2008-09-25
WO2003018005A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
DE60323090D1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
BR0311313A (pt) Derivados de diaril uréia úteis para o tratamento de doenças dependentes de proteìna cinase
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
DK1341524T3 (da) Farmaceutisk præparat i form af en pasta omfattende en syre-labil aktiv bestanddel
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
DE60233433D1 (de) PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN
ATE404192T1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
ATE157871T1 (de) Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind
DE602004031631D1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
BR0104586A (pt) Método para tratamento de neurodegeneração
DE602004029993D1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
ATE331523T1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
ATE440835T1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
DE602004025103D1 (de) Heilkräuterzusammensetzung zur Behandlung von AIDS
DE68916651D1 (de) Heilmittel zur behandlung von toxoplasmose.
ATE491474T1 (de) Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor- antagonists
RU2000125000A (ru) Состав для антисептической обработки кожи рук и операционного поля
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
ATE370733T1 (de) Pharmazeutische kombinationspräparat zur behandlung von spastischkeit und/oder schmerzen
ATE284696T1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties